Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

Implantica reported a mixed financial performance for Q4 2024, with a 30% year-over-year decrease in quarterly revenue to €442,000, while full-year net sales rose by 38% to €1.9 million. The company's ...

"She does appear like an Amber Heard to me," the SiriusXM host adds The post Megyn Kelly Says Blake Lively Has ‘Absolutely ...